7 known cases. View patent page →
Celgene asserted multiple patents, including the '554 patent, against Natco's lenalidomide ANDA No. 201452. The '554 claims were dismissed without prejudice by stipulation on March 26, 2015; the overall case settled with a consent judgment entered January 4, 2016, and terminated January 5, 2016.
Celgene sued Hetero entities; aggregator data lists patent 7,119,106 as involved in this case, but the narrative flags this as unverified and notes the published opinions centered primarily on Pomalyst and later-expiring Revlimid patents rather than the expired '106 patent.
Antitrust litigation by purchaser/insurer classes against Celgene/BMS, in which the '106 patent is directly referenced as part of Celgene's Revlimid patent portfolio/alleged monopolization scheme. The case remains ongoing with appeals and summary-judgment briefing in 2024 (see Dkt. 446, 2:19-cv-07532).
Clayton Act antitrust action by Blue Cross and Blue Shield Association against Celgene, referencing the '106 patent as part of Celgene's Revlimid patent portfolio/alleged monopolization scheme. The case was terminated/transferred, with an aggregator-listed termination date around April 18, 2021.
Consumer/purchaser antitrust action against Celgene, docketed in the District of Minnesota and terminated December 2, 2020. The '106 patent is referenced as part of Celgene's Revlimid patent portfolio/alleged monopolization scheme.
Removed antitrust action against Celgene, docketed in the District of Minnesota and terminated March 22, 2021. The '106 patent is referenced as part of Celgene's Revlimid patent portfolio/alleged monopolization scheme.
Purchaser antitrust action against Celgene, docketed in the District of New Jersey and terminated March 31, 2015, likely consolidated/transferred. The '106 patent is referenced as part of Celgene's Revlimid patent portfolio/alleged monopolization scheme.